Pavullo Nel Frignano

This observational study investigates the impact of surgical centralization and treatment strategies on oncologic outcomes in female patients diagnosed with epithelial ovarian cancer EOC between 2018 and 2023 within the Emilia-Romagna region in Italy. The study aims to compare progression-free survival and overall survival across three time periods before centralization and the COVID-19 pandemic, during the pandemic peak, and during the post-pandemic control phase. This research is conducted by the AUSL-IRCCS of Reggio Emilia and includes both retrospective and prospective components. Participants are grouped based on when they received treatment prior to centralization and the pandemic 2018-2019, during the peak pandemic with changes in care due to resource limitations 2020-2021, and after the pandemic peak reflecting new care standards 2022-2023. No experimental treatments are given, as all patients receive standard care according to routine clinical practice. The study observes variations in surgical approaches, chemotherapy, and use of therapies like Bevacizumab and PARP inhibitors. Throughout the study, participants clinical records and outcomes are reviewed retrospectively, with ongoing clinical follow-up planned for up to five years. Researchers assess survival rates, treatment types, tumor characteristics, recurrence patterns, and use of secondary treatments including surgery and radiotherapy. Data collection includes information from multidisciplinary tumor boards and patient consents. The study spans until June 2031, allowing comprehensive evaluation of long-term outcomes.

Postural abnormalities such as Pisa Syndrome PS and camptocormia cause significant disability in people with Parkinsons disease PD, affecting their posture, mobility, and quality of life. PS involves a lateral trunk flexion often greater than 10 degrees, with features like axial rotation and poor awareness of posture, while camptocormia is characterized by an anterior forward flexion of the trunk. Current treatments including medication, physiotherapy, botulinum toxin, and brain stimulation offer limited and short-lasting benefits, creating a need for innovative rehabilitation approaches. This study evaluates the use of an AI-powered real-time visual feedback system called the Kemtai platform as a home-based rehabilitation tool after inpatient neurorehabilitation for PD patients with postural disorders. The intervention provides personalized exercise routines with real-time corrective feedback through video analysis, aiming to support continued improvement in posture and mobility. Participants first complete 4 to 8 weeks of hospital-based neurorehabilitation, then use the AI system at home to maintain and enhance their gains. Participants will be assessed at baseline, after 6 to 8 weeks of AI-based home rehabilitation, and again after 4 weeks to measure posture, mobility, and quality of life using clinical tests and motion analysis. User satisfaction, system usability, and safety will also be evaluated. The study seeks to provide evidence on the feasibility and potential benefits of AI-driven home rehabilitation to promote long-term functional improvements and greater independence in people with PD.

Researchers are studying how best to manage patients with low blood pressure due to traumatic injuries before they reach the hospital. The study focuses on patients helped by helicopter emergency medical services HEMS across Italy, where emergency care practices vary widely. The goal is to understand how prehospital treatments affect hospital recovery and survival, especially for those with severe bleeding and shock. The study observes different prehospital treatments such as drug use including antifibrinolytics, pain relief, sedatives, and muscle relaxants. It also looks at advanced techniques like resuscitative endovascular balloon occlusion of the aorta REBOA, blood transfusions, and ultrasound assessments for trauma. Care strategies like staying on scene for treatment versus rapid transport are also compared as part of usual prehospital management. Participants will have detailed data collected from the prehospital phase including demographics, trauma type, and treatments given. Hospital data such as blood transfusions, lab results, length of hospital and ICU stays, use of ventilation or kidney support, recovery, and survival will be analyzed. The main outcome measured is mortality within 30 days, with secondary outcomes including survival to hospital admission, hospital stay length, blood products used, and transport times. The study started in May 2021 and will continue until May 2026.